{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-267659","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-11T20:30:16+00:00","discovered_at":"2026-06-11T20:31:05.670868+00:00","generated_at":"2026-06-11T20:36:50.655736+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulcrum approves retention bonuses for CEO, CLO, CFO; accounting officer departs after restructuring","bullets":["CEO Alex Sapir receives $370,040 retention bonus; CLO Curtis Oltmans $195,480; CFO Alan Musso $195,200.","Bonuses payable on change in control or termination without cause after fulfilling transitional duties.","VP+ level employees added to change-in-control severance if terminated within 6 months before a CIC.","VP Finance & principal accounting officer Greg Tourangeau departs mutually; no disagreement on financial matters.","Restructuring follows discontinuation of pociredir for sickle cell disease, previously disclosed May 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-267659","json":"https://secwatch.observer/filing/0001193125-26-267659.json","markdown":"https://secwatch.observer/filing/0001193125-26-267659.md","text":"https://secwatch.observer/filing/0001193125-26-267659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/0001193125-26-267659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/fulc-20260605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:36:50.655736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"292cbce1b3","claim":"Greg Tourangeau departed as Vice President, Finance and principal accounting officer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On June 10, 2026, Fulcrum and Greg Tourangeau, Fulcrum’s Vice President, Finance and principal accounting officer, mutually agreed that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed between Mr. Tourangeau and Fulcrum.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/0001193125-26-267659-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Vice President, Finance and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}